XML 37 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
Business Segment Information (Tables)
 12 Months Ended
Apr. 30, 2016
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following tables summarize, for the periods indicated, operating results by business segment (in thousands):
Year Ended April 30, 2016
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
$
1,972

 
$
9,210

 
$
—

 
$
11,182

Direct cost of services
(2,075
)
 
(6,553
)
 
—

 
(8,628
)
Sales and marketing costs
(833
)
 
(2,414
)
 
—

 
(3,247
)
Other operating expenses
—

 
(3,886
)
 
(3,138
)
 
(7,024
)
Stock compensation expense (1)
—

 
—

 
(2,599
)
 
(2,599
)
 
 
 
 
 
 
 
 
Segment profit (loss)
$
(936
)
 
$
(3,643
)
 
$
(5,737
)
 
$
(10,316
)
Year Ended April 30, 2015
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
$
1,663

 
$
7,200

 
$
—

 
$
8,863

Direct cost of services
(2,711
)
 
(4,877
)
 
—

 
(7,588
)
Sales and marketing costs
(1,514
)
 
(2,208
)
 
—

 
(3,722
)
Other operating expenses
—

 
(4,493
)
 
(3,136
)
 
(7,629
)
Stock compensation expense (1)
—

 
—

 
(3,162
)
 
(3,162
)
 
 
 
 
 
 
 
 
Segment loss
$
(2,562
)
 
$
(4,378
)
 
$
(6,298
)
 
$
(13,238
)
 
(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses in the table above, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments. See Note 6 for the allocation of stock compensation expense relative to the individual line items as it is reported on the Company's Consolidated Statement of Operations.